Direct-acting antiviral agents are not associated with an increased risk of hepatocellular carcinoma recurrence in liver transplant recipients with hepatitis C

被引：0
|
作者：
Tse, Chung Sang [1 ,2 ]
Yang, Judong [3 ]
Mousa, Omar [3 ,4 ]
Pungpapong, Surakit [4 ]
Keaveny, Andrew [4 ]
Nelson, Kevin [3 ]
Bashar, Aqel [5 ]
Dickson, Rolland [5 ]
Vargas, Hugo E. [5 ]
Gores, Gregory [3 ]
Roberts, Lewis [3 ]
Leise, Michael [3 ]
机构：
[1] Brown Univ, Gastroenterol, Providence, RI 02912 USA
[2] Mayo Clin, Internal Med, Rochester, MN USA
[3] Mayo Clin, Gastroenterol & Hepatol, Rochester, MN USA
[4] Mayo Clin, Gastroenterol & Hepatol, Jacksonville, FL 32224 USA
[5] Mayo Clin, Gastroenterol & Hepatol, Scottsdale, AZ USA
来源：
JOURNAL OF HEPATOLOGY | 2019年 / 70卷 / 01期
关键词：
D O I：
10.1016/S0618-8278(19)31140-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI-401
引用
收藏
页码：E571 / E571
页数：1
相关论文
共 50 条
  • [1] DIRECT-ACTING ANTIVIRAL AGENTS ARE NOT ASSOCIATED WITH AN INCREASED RISK OF HEPATOCELLULAR CARCINOMA RECURRENCE IN LIVER TRANSPLANTATION RECIPIENTS WITH HEPATITIS C
    Tse, Chung Sang
    Yang, Ju Dong
    Mousa, Omar Y.
    Pungpapong, Surakit
    Keaveny, Andrew
    Nelson, Kevin
    Aqel, Bashar
    Dickson, Rolland C.
    Vargas, Hugo E.
    Gores, Gregory J.
    Roberts, Lewis R.
    Leise, Michael D.
    GASTROENTEROLOGY, 2019, 156 (06) : S1222 - S1222
  • [2] Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
    Ashokkumar Jain
    Danielle Miller
    Ian Schreibman
    Thomas R. Riley
    Karen L. Krok
    Takehiko Dohi
    Rajeev Sharma
    Zakiyah Kadry
    Hepatology International, 2019, 13 : 190 - 198
  • [3] Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
    Jain, Ashokkumar
    Miller, Danielle
    Schreibman, Ian
    Riley, Thomas R., III
    Krok, Karen L.
    Dohi, Takehiko
    Sharma, Rajeev
    Kadry, Zakiyah
    HEPATOLOGY INTERNATIONAL, 2019, 13 (02) : 190 - 198
  • [4] Therapy With Direct-Acting Antiviral Agents for Hepatitis C in Liver Transplant Recipients
    Nogueras Lopez, F.
    Lopez Garrido, A.
    Ortega Suazo, E. J.
    Vadillo Galles, F.
    Valverde Lopez, F.
    Espinosa Aguilar, M. D.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (02) : 631 - 633
  • [5] Timing of Hepatitis C Antiviral Therapy in Liver Transplant Recipients With Direct-acting Agents
    Suraweera, Duminda
    Saab, Elena G.
    Tong, Myron J.
    Saab, Sammy
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2016, 14 (03) : 243 - 251
  • [6] Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy
    Lim, Nicholas
    Singh, Dupinder
    Jackson, Scott
    Lake, John R.
    GASTROINTESTINAL TUMORS, 2020, 7 (04) : 134 - 143
  • [7] Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
    Tse, Chung Sang
    Yang, Ju Dong
    Mousa, Omar Y.
    Nelson, Kevin M.
    Pungpapong, Surakit
    Keaveny, Andrew
    Aqel, Bashar A.
    Vargas, Hugo
    Dickson, Rolland C.
    Watt, Kymberly
    Gores, Gregory J.
    Roberts, Lewis R.
    Leise, Michael D.
    TRANSPLANTATION DIRECT, 2021, 7 (01): : E635
  • [8] End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma
    Hernaez, Ruben
    Thimme, Robert
    GUT, 2022, 71 (03) : 454 - 456
  • [9] Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
    Lee, Chang Hun
    Kim, In Hee
    GUT AND LIVER, 2021, 15 (03) : 327 - 328
  • [10] Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients
    Akamatsu, Nobuhisa
    Togashi, Junichi
    Hasegawa, Kiyoshi
    Kokudo, Norihiro
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S598 - S602
12345